ENVB Stock Dips After-Hours On Widening Q4 Loss Despite Study Progress On Psychiatry Drug

• The company said that it is now in the process of completing pre-clinical studies for its lead candidate EB-003.
• The company is looking forward to submitting an application to the FDA, seeking permission to commence human trials.
• The drug is aimed at delivering fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

Shares of Enveric Biosciences (ENVB) fell 4% after hours on Friday on the heels of the company reporting wider loss for the fourth-quarter (Q4) of 2025 compared to the same period of the previous year.

For Q4 2025, the company reported a net loss of $4 million, higher than the loss of $3.2 billion reported for the corresponding quarter of 2024.

Plans Ahead

The company said that it is now in the process of completing pre-clinical studies for its lead candidate EB-003.

EB-003 is a non-hallucinogenic drug being developed for the treatment of underserved mental health conditions. The company is looking forward to submitting an application to the U.S. Food and Drug Administration seeking permission to commence human trials. In preclinical studies, the candidate showed potential in treating severe chronic depression, despair and post-traumatic stress disorder.

“In 2026, we are working towards a streamlined IND application for EB-003 in preparation of the initiation of a first-in-human Phase 1 clinical trial. With the dual mechanism of action that engages both 5-HT2A and 5-HT1B receptors, we are optimistic that our research has the potential to profoundly impact mental health disease where innovation has been lacking for decades,” CEO Joseph Tucker said. The drug is aimed at delivering fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

How Did Retail Traders React?

On Stocktwits, retail sentiment around ENVB stock stayed within the ‘bearish’ territory at the time of writing while message volume rose from ‘low’ to ‘normal’ levels.

ENVB stock has lost nearly 90% of its value over the past 12 months. 

Read More: ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

For updates and corrections, email newsroom[at]stocktwits[dot]com.